George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Should be a good day here tomorrow... 10% will do for starters
GSK defeated thousands of US lawsuits claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science. The ruling by US district judge Robin Rosenberg knocks out 50,000 claims in federal court. A spokesperson for GSK said the company welcomed the decision.
Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.
I'm small beer, only 1047 pints for me, just 698 at current level ...
Excellent news about Jemperli being the first immunotherapy that works for endometrial cancer. Surprisingly common cancer.
thats 82500 pints for me
That's 28000 pints for me then. Really need to exit this share and into something else.
Buy 3 pints per share.
What could we all do with £20 a share for our GSK? I shall try not to think about it until it happens!
Thanks for that .no wonder I couldn’t find it. :-).
GSK is a potential buyout candidate for Novartis - Intron Health”
GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London.
The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology.
In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal.
Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025.
The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition.
hTTps://seekingalpha.com/news/3912660-gsk-stock-gains-on-buyout-claims-linked-to-novartis?
Not really “news”. Article from 19 August 2022.
https://www.pmlive.com/pharma_news/gsk_awarded_first-ever_unicef_contract_for_malaria_vaccine_in_deal_worth_170m_1453562?SQ_ACTION=clear_design_name&full=true
Source please. I couldn’t find any news.
First-ever supply of a malaria vaccine, with a value of up to $170m over 3 years potentially saving thousands of lives each year. Nice one.
For those with a subscription to the Financial Times:
https://on.ft.com/3GUa5KP
According to the pink one, latest perspective : fewer claims, lower settlements, lower liabiliy, hedge funds positioning for good news, fewer shares on loan, sp recovery well behind that of other companies.
Court ruling on the submissibility of evidence (Daubert hearing) imminent.
Seems good news expected before Xmas...
that’s a little dumb, look at last 22yrs. it still hasn’t risen above 2100p..
LOOK AT
ABBVIE
JNJ
ROCHE
VERTEX
ASTRA
Gsk has been held back for decades due to high divi, just like RDS & BP compared to US counterparts
I have bought and sold these for over 20 years. Made a bit of a profit each time. Now I am only in for the dividend. Looking at a few of my other favourites, I could have been in and out several times with a decent profit in the time I have held these.
Think it's time to exit GSK after 5 years. Been a dog compared to other major pharmas.....divi has kept me here, the SP sure hasn't !!!
Getting out of theoretical gene therapy treatment returning to practical antibiotics seems a good move.
....coming from GSK these days?
Its a fast slow pace now .....to ex dividend date...atb
SP moving up slowly, then may well pick up a pace.
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-phase-iia-study-results-for-a-new-first-in-class-candidate-medicine/
" Roche late-stage Alzheimer’s trials end in failure "
Sack the CEO, the buck stops there !!
I have much larger holdings of big companies in my portfolio. PepsiCo is 12% legal and general 10% rio tinto 10% realty income 9% . Quite comfortable with this . The more risky high growth potential stuff is all 3% or so.
Quiye
One company should only make ~3% of a portfolio, so why do people get so aggrieved?
Well that's a lot of bollards. What if your portfolio only totals £10,000 or less as I'm sure many do? And if you have a large portfolio, having 30+ holdings risks being a tracker unless you know what you are doing, and many don't. GSK makes up 4% of mine give or take, but LGEN makes up 7% and LLOY 6%, (though that is temporary). I am a buy and holder and hate selling. At least GSK pays a div, though the board really needs their ****s kicked. Where has Eliot gone?